Astrocytoma
Drug research and approvals for astrocytoma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 319 studies of astrocytoma are recruiting on ClinicalTrials.gov, Health Canada has authorized 2 drug trials for it since 2013, FDA has 5 approved and 2 open orphan designations naming it, and the EU has 1 authorised medicine for it.
- Recruiting worldwide: 319
- Trials authorized in Canada: 2
- FDA orphan approvals: 5
- EU medicines: 1
- Advanced Imaging-Guided Standard Versus Dose-Intensified Radiation Therapy for the Treatment of Newly Diagnosed…NCT07935889 · Phase 3 · Mayo Clinic · starts Nov 13, 2026
- A Phase I Clinical Study of YN003 in the Treatment of GliomaNCT07929909 · Phase 1 · Beijing Inno Medicine Co., Ltd. · starts Oct 27, 2026
- Observational Connectomics in Adults Undergoing Resection of WHO II-IV GliomaNCT07927595 · Not reported · Northwell Health · starts Feb 1, 2026
- Window of Opportunity Study of Lixumistat in Patients With Newly Diagnosed GlioblastomaNCT07884344 · Early Phase 1 · Macarena De La Fuente, MD · starts Dec 1, 2026
- Diffuse Gliomas in Reunion Island: Establishment of an Epidemiological, Clinical-biological and Socio-anthropological…NCT07865195 · Not reported · Centre Hospitalier Universitaire de la Réunion · starts Apr 7, 2025
- TMZ + RT + 5-ALA + LIDU SDT System for Newly Diagnosed Butterfly GliomaNCT07862647 · Phase 1 · Alpheus Medical, Inc. · starts Oct 29, 2026
- Metabolomics and Transcriptomics of Low- and High-Grade GliomasNCT07832734 · Not reported · I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio · starts Apr 1, 2026
- VISTA: Valproic Acid, Irinotecan, and Simvastatin for Recurrent GliomaNCT07831369 · Phase 2 · Inova Health Care Services · starts Sep 4, 2026
- REMIND Maintenance Radiotherapy for Newly Diagnosed GlioblastomaNCT07831772 · Not applicable · University of Minnesota · starts Aug 24, 2026
Approved 6
- TemozolomideGlioblastoma · DNA inhibitor
- BevacizumabGlioblastoma · Vascular endothelial growth factor A inhibitor
- CarmustineGlioblastoma · Glutathione reductase inhibitor
- EverolimusFK506-binding protein 1A inhibitor
- VorasidenibIDH1/IDH2 inhibitor
- TrametinibGlioblastoma · Dual specificity mitogen-activated protein kinase kinase 2 inhibitor
Phase 3 12 of 27
- LomustineGlioblastoma · DNA inhibitor
- NivolumabGlioblastoma · Programmed cell death protein 1 inhibitor
- CarboplatinGlioblastoma · DNA inhibitor
- IpilimumabGlioblastoma · Cytotoxic T-lymphocyte protein 4 inhibitor
- Cintredekin besudotoxGlioblastoma · Interleukin 13 receptor binding agent
- CilengitideGlioblastoma · Integrin alpha-V/beta-3 antagonist
- HydroxyureaGlioblastoma · Ribonucleoside-diphosphate reductase RR1 inhibitor
- DianhydrogalactitolGlioblastoma · DNA cross-linking agent
- Depatuxizumab mafodotinGlioblastoma · Epidermal growth factor receptor erbB1 binding agent
- CediranibGlioblastoma · Stem cell growth factor receptor inhibitor
- ImatinibGlioblastoma · Tyrosine-protein kinase ABL inhibitor
- ChloroquineGlioblastoma · Ferriprotoporphyrin IX inhibitor
Phase 2 12 of 176
- PembrolizumabGlioblastoma · Programmed cell death protein 1 inhibitor
- IrinotecanGlioblastoma · DNA topoisomerase I inhibitor
- DisulfiramGlioblastoma · Aldehyde dehydrogenase inhibitor
- Aminolevulinic acidGlioblastoma · DNA inhibitor
- MetforminGlioblastoma · Mitochondrial complex I (NADH dehydrogenase) inhibitor
- SunitinibGlioblastoma · Macrophage colony stimulating factor receptor inhibitor
- VorinostatGlioblastoma · Histone deacetylase 1 inhibitor
- TemsirolimusGlioblastoma · FK506-binding protein 1A inhibitor
- HiltonolGlioblastoma
- CetuximabGlioblastoma · Epidermal growth factor receptor erbB1 inhibitor
- ErlotinibGlioblastoma · Epidermal growth factor receptor erbB1 inhibitor
- CatequentinibGlioblastoma · Vascular endothelial growth factor receptor 2 inhibitor
Phase 1 or earlier 12 of 133
- CyclophosphamideGlioblastoma · DNA inhibitor
- ImiquimodGlioblastoma · Toll-like receptor 7 agonist
- FludarabineGlioblastoma
- RibociclibGlioblastoma · Cyclin-dependent kinase 4 inhibitor
- Mycophenolate mofetilGlioblastoma · Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor
- PaclitaxelGlioblastoma · Tubulin inhibitor
- SulfasalazineGlioblastoma · Arachidonate 5-lipoxygenase inhibitor
- VoxtalisibGlioblastoma · Serine/threonine-protein kinase mTOR inhibitor
- Motexafin gadoliniumGlioblastoma · Thioredoxin reductase 1 inhibitor
- Nalotimagene carmaleucelGlioblastoma · Cell therapy
- PamiparibGlioblastoma · Poly [ADP-ribose] polymerase-1 inhibitor
- Perifosine
How its trials ended
394 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 116 whose ending is known, 17% met their primary endpoint, 10% missed it and 72% stopped early.
- Completed, result not reported15840%
- Ongoing9023%
- Stopped: other or unclear379%
- Status unknown308%
- Stopped: enrollment or feasibility226%
- Met its primary endpoint205%
- Stopped: sponsor or business decision174%
- Missed its primary endpoint123%
- Stopped: lack of efficacy41%
- Stopped: funding31%
- Stopped: safety1<1%
| Mar 31, 2017 | A phase 3, randomized, open-label study to evaluate the efficacy and safety of eflornithine with lomustine compared to lomustine alone in patients with…Eflornithine | Orbus Therapeutics | Ongoing |
| Aug 5, 2015 | Phase 2/3 randomized, open-label study of toca 511, a retrovial replicating vector, combined with toca fc versus standard of care in subjects undergoing…Toca 511/ Toca fc | Tocagen | Ongoing |
| Aug 6, 2024 | VoranigoTreatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible isocitrate… | Servier Pharmaceuticals LLC | Approved |
| Apr 10, 2018 | AfinitorFor the adjunctive treatment of adult and pediatric patients age 2 years and older with tuberous sclerosis complex (TSC)-associated… | Novartis Pharmaceuticals Corp. | Approved |
| Apr 26, 2012 | AfinitorTreatment of adults with renal angiomyolipoma and tuberous sclerosis complex (TSC) not requiring immediate surgery. | Novartis Pharmaceuticals Corp. | Approved |
| Oct 29, 2010 | AfinitorTreatment of patients with subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis who require therapeutic… | Novartis Pharmaceuticals Corp. | Approved |
| Aug 11, 1999 | TemodarTreatment of adult patients with refractory anaplastic astrocytoma, i.e., patients at first relapse who have experienced disease… | Schering-Plough Research Institute | Approved |
| Jul 24, 2019 | (R)-6-((3,3-difluoro-1-methylpiperidine-4-yl)oxy-N-(3-ethyny…Treatment of glioma (including glioblastoma and anaplastic astrocytoma) | Wayshine Biopharm Inc. | Designated |
| Feb 12, 1999 | Iodine I-131 radiolabeled chimeric MAb tumor necrosis…Treatment of glioblastoma multiforme and anaplastic astrocytoma. | Peregrine Pharmaceuticals, Inc. | Designated |
| Authorised | Medicine | Holder | EPAR |
|---|---|---|---|
| Sep 17, 2025 | VoranigoVorasidenib · orphan | Les Laboratoires Servier | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA